



FIG. 1




**BEST AVAILABLE COPY** 









**BEST AVAILABLE COPY** 

## **DEVDase ACTIVITY**






FIG.3B

PCT/CA2004/000152





8/14





TABLE II. COMPARATIVE POTENCIES OF CASPASE INHIBITORS MEASURED BY M808 AND DNA FRAGMENTATION											
CELL LINE	INHIBITOR	IC50 PROBE (µM)	IC50 DNA CLEAVAGE (μM)								
NT2 NT2 NT2 JURKAT JURKAT THYMOCYTES THYMOCYTES	M791 M826 M090 M791 M826 M826 M867	0.5 0.045 3.6 2.5 0.045 0.07 0.09	0.4 0.03 7 4.8 TO BE DETERMINED 0.14 0.27								

FIG.4C

PCT/CA2004/000152





201542684




FIG.5B





TABLE III. PERCENT OCCUPANCY	0F	CASPASE	ACTIVE	SITE	BY M	1867	IN APC	PTOTIC	RAT	THYMOCYTES
	1	2	3	4	5		6	7	8	9
M867 CONCENTRATION (µM)	'n	Õ	0.005	0.025	5 0.	05	0.1	0.25	1	5
M867 CUNCENTRATION (AM)	0.6	14.3	17.6	19.0	17	7.1	19.2	11.3	10.	2 4.6
p17 DENSITOMETRY	0.0	11.0	52.7	56.9	5	1.4	57.6	34.0	30.	
EXPECTED 1251 M808 SIGNAL*	4.7	42.6	42.8	40.4	39	9.1	28.4	11.9	3.7	0.0
ACTUAL 1251 M808 SIGNAL	4.1	72.0	0.8	0.7	0.	8.	0.5	0.4	0.1	0.0
RATIO ACTUAL/EXPECTED			81	71	7	6	49	35	12	0
% FREE ACTIVE SITES			19	29	2	4	51	65	88	100
% OCCUPANCY									125-2	

<sup>\*</sup> EXPECTED [1251]M808 SIGNAL CALCULATED BASED ON p17 DENSITOMETRY vs [1251]-M808 SIGNAL IN ABSENCE OF DRUG

FIG.5C






FIG.6A




FIG.6B




FIG.6C

BEST AVAILABLE COPY




FIG.7

**BEST AVAILABLE COPY**